Therapy Areas: Vaccines
Anivive's GC376 Reduces COVID-19 Replication, Shows Potential as New Post-Infection Treatment
26 July 2021 - - Scientific journals The Proceedings of the National Academy of Sciences has released a research article detailing the effectiveness of US-based biotechnology company Anivive's GC376 in preventing the reproduction of SARS-CoV-2, the virus that causes COVID-19, the company said.

While vaccines to help prevent COVID-19 are now expansively available in the United States, the need for post-infection treatment options is on the rise.

The PNAS article, "Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection," details a study that shows mice with fatal SARS-CoV-2 infections experienced reduced viral load and improved survival when treated with deuterated variants of GC376, an antiviral medication under development by Anivive Lifesciences.

All coronaviruses, including SARS-CoV-2, contain a protease responsible for replication of the virus. GC376 is a protease inhibitor, designed to block the replication process and stop the virus from spreading.

For the study, mice infected with SARS-CoV-2 that developed lung pathology resembling that of severe COVID-19 in humans were given a series of deuterated variants of GC376 to evaluate the antiviral effect against SARS-CoV-2. Treatment was started 24 hours after infection.

Study results show GC376 has excellent therapeutic efficacy as an antiviral agent against SARS-CoV-2.

Anivive, a biotechnology company focused on pet health, has been developing GC376 since 2018 to treat a deadly cat disease caused by a coronavirus. Feline Infectious Peritonitis is the leading cause of death in kittens and young cats, affecting up to 1 in 300 cats worldwide.

The University of California in Davis conducted field tests for the use of GC376 in cats with FIP. GC376 resulted in a reversal of symptoms within 48 hours with no significant side effects.

GC376 has the potential to be a One Health medicine, providing therapeutic benefits to both pets and people.

Anivive has filed a pre-Investigational New Drug request with the Food and Drug Administration to evaluate GC376 as a post-infection treatment of COVID-19 in humans.

GC376 is a broad-spectrum antiviral medicine under development by Anivive Lifesciences for therapeutic use in animals and humans.

A first-in-class small molecule protease inhibitor, GC376 blocks 3CLpro, a protease common to many coronaviruses, with high therapeutic efficacy. 

Anivive licensed exclusive worldwide patent rights to GC376 from Kansas State University.

Anivive's proprietary software accelerates the delivery of new, affordable treatments for pets.

Backed by over USD 45m in seed funding, Anivive has gained conditional approval for LAVERDIA-CA1 (verdinexor), the first oral tablet to treat canine lymphoma and created a specialty sales force dedicated to supporting veterinarians.

Anivive's pipeline includes 8+ first-in-class pharmaceuticals, biologics, and vaccines.